• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

58.43 -0.59 (-1.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
3 Mid-Cap Stocks That Concern Us
December 03, 2025
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
News headline image
Royalty Pharma to Present at Upcoming Investor Conferences
November 26, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
November 18, 2025
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model. 
Via Investor's Business Daily
News headline image
3 Value Stocks with Warning Signs
November 17, 2025
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Topics Supply Chain
News headline image
Earnings Scheduled For November 5, 2025 ↗
November 05, 2025
 
Via Benzinga
News headline image
How Do Investors Really Feel About Royalty Pharma? ↗
September 16, 2025
 
Via Benzinga
News headline image
3 Low-Volatility Stocks We Find Risky
November 16, 2025
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q3 Earnings?
November 12, 2025
Royalty Pharma trades at $39.59 and has moved in lockstep with the market. Its shares have returned 20.6% over the last six months while the S&P 500 has gained 16.4%. 
Via StockStory
Topics Stocks Supply Chain
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
November 06, 2025
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
News headline image
Stocks Rebound, Eli Lilly Jumps To 14-Month Highs: What's Moving Markets Wednesday? ↗
November 05, 2025
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid solid corporate earnings and growing signs that the Federal Reserve may be nearing... 
Via Benzinga
Topics Economy
News headline image
Royalty Pharma (NASDAQ:RPRX) Q3 2025 Earnings Beat Estimates and Raise Guidance ↗
November 05, 2025
Royalty Pharma's Q3 2025 earnings beat estimates, with strong revenue and EPS. The company also raised its full-year 2025 guidance. 
Via Chartmill
Topics Earnings
News headline image
Royalty Pharma Reports Third Quarter 2025 Results
November 05, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences
November 04, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2
November 03, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
What To Expect From Royalty Pharma’s (RPRX) Q3 Earnings
November 03, 2025
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
ROYALTY PHARMA PLC-CL A (RPRX) Shows Strong Technicals and a High-Quality Breakout Setup ↗
November 01, 2025
RPRX stock shows strong technical momentum and a high-quality consolidation pattern, signaling a potential breakout above key resistance. 
Via Chartmill
News headline image
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗
October 31, 2025
Via MarketBeat
News headline image
2 Reasons to Avoid RPRX and 1 Stock to Buy Instead
October 29, 2025
While the S&P 500 is up 23.9% since April 2025, Royalty Pharma (currently trading at $36.80 per share) has lagged behind, posting a return of 12.5%. This was partly due to its softer quarterly results... 
Via StockStory
Topics Government Stocks Supply Chain
News headline image
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data ↗
October 28, 2025
Via MarketBeat
News headline image
Royalty Pharma Declares Fourth Quarter 2025 Dividend
October 17, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
3 Healthcare Stocks We Keep Off Our Radar
October 13, 2025
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the... 
Via StockStory
Topics Economy Stocks
News headline image
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
October 09, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
September 29, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
September 19, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore
September 17, 2025
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company’s Plans to Drive Value Creation
September 11, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Release of Deloitte’s Report on the Biopharma Royalty Market
September 10, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
1 Mid-Cap Stock with Exciting Potential and 2 Facing Challenges
September 08, 2025
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
Topics Economy
News headline image
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
September 04, 2025
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
September 02, 2025
From Royalty Pharma plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap